周五盘中，吉利德科学股价大涨8.05%，引发投资者广泛关注。此次显著上涨主要受到公司发布的强劲财报以及分析师对其新药的积极评价推动。
根据吉利德科学公布的2025年第二季度财报，公司实现调整后每股收益2.01美元，超过分析师预期的1.96美元。季度收入同比增长2%至70.8亿美元，同样高于市场预期的69.8亿美元。公司还上调了全年销售预期，预计全年产品销售额在283亿美元至287亿美元之间。其中，除瑞德西韦外的产品销售额同比增长4%，达69亿美元，显示出公司核心业务的稳健增长。
此外，华尔街分析师对吉利德科学新推出的艾滋病预防药物Yeztugo持乐观态度。多家券商上调了吉利德科学的目标价，其中摩根大通将目标价从130美元上调至135美元，TD Cowen将目标价从110美元上调至115美元。分析师普遍认为，公司在PrEP（艾滋病暴露前预防）领域的布局将取得成功，Yeztugo的上市前景令人鼓舞。这些积极因素共同推动了吉利德科学股价的大幅上涨，反映出投资者对公司未来发展前景的信心增强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.